Achilles Therapeutics (ACHL) PT Lowered to $17 at Chardan Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel deepen AI capex concerns
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts ACHL Hot Sheet
Price: $1.48 --0%
Rating Summary:
2 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 44 | New: 9
Rating Summary:
2 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 44 | New: 9
Join SI Premium – FREE
Chardan Capital Markets analyst Geulah Livshits lowered the price target on Achilles Therapeutics (NASDAQ: ACHL) to $17.00 (from $20.00) while maintaining a Buy rating.
You May Also Be Interested In
- Amrize Ltd (AMRZ) PT Raised to $43 at DA Davidson
- Digital Realty Trust (DLR) PT Raised to $229 at Bernstein SocGen Group
- Stryker (SYK) PT Lowered to $375 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
